電訊首科(03997.HK)斥400萬元購股票掛鉤定息票據
電訊首科(03997.HK)公布,全資附屬於今日(11日)購入由瑞銀集團發行的股票掛鉤定息票據,票據息率12%,涉及400萬元(未計及交易費用),將以內部資源撥付,年期為6個月,到期日為2021年11月29日。
掛鉤股票分別為港交所(00388.HK)及騰訊(00700.HK),港交所發行價為443.6元,行使價401.2362元;騰訊控股發行價578元,行使價522.801元。
公司認為,定息票據具吸引票面利率,並能產生高於銀行定期存款的潛在利息收益,於股權、行使價格及年期方面擁有相對靈活的選擇,預期可提高潛在回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.